Posted on 09/12/2009 in Pharmaceutical Company Product News Bayer has revealed that its endometriosis therapy Visanne has been approved for marketing in Europe.
The recommendation for the once-daily oral tablet was made this week following the results of a clinical trial which found that the drug is effective in the relief of endometriosis pain, has been shown to reduce lesions and demonstrates safety and tolerability.
It is indicated for short-term use only, as safety concerns - such as decreased bone mineral density and side effects such as hot flushes - currently limit its prolonged use.
Phil Smits, head of Bayer's women's healthcare business unit, stated: "Patients often need to use different combinations of the available treatment options and even undergo repeat surgical procedures. There is therefore a high medical need for new treatment options."
In related news, Bayer this week announced that 20 mg once-daily doses of its novel oral anticoagulant rivaroxaban yielded positive results during a phase III trial. Other news stories from 09/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
